As threat of antibiotic yeast infection symptoms female resistance mounts, biotechs are running out of cash and time

While the pharmaceutical industry’s powerhouses continue wrestling with lawmakers to gut drug pricing yeast infection symptoms female measures from the agenda, biotechnology companies deep in the antibiotic space are desperate for yeast infection symptoms female capitol hill to take decisive action on an issue somewhat yeast infection symptoms female less likely to command center stage: “superbugs.” the handful of drugmakers focused on developing new antibiotics to yeast infection symptoms female combat these drug-resistant bacteria are running dangerously low on cash, and run the risk of declaring bankruptcy.

The public health community has long fought to raise awareness yeast infection symptoms female of the imminent threat posed by superbugs. Every year, about 2 million U.S. Residents become infected with drug-resistant bacteria; tuberculosis, malaria, HIV and other drug-resistant infections kill nearly 700,000 people worldwide. It’s been just over 30 years since scientists last discovered yeast infection symptoms female a new class of antibiotics. If another three decades pass without meaningful progress, experts warn, the annual death toll from drug-resistant infections is estimated to hit 10 million.

Without new treatment for infections that can arise from procedures yeast infection symptoms female ranging from caesarean sections to hip replacement surgery, what are now common medical operations could rapidly become life-threatening. But despite the looming risk, which has pushed a wave of young biotechnology companies to yeast infection symptoms female seek aggressive congressional and regulatory action, investors still aren’t biting.

“I’ve been speaking with a lot of potential investors on yeast infection symptoms female the private side and on the public side,” said zach zimmerman, chief executive officer at san diego-based forge therapeutics inc. “the message I’m hearing about antibiotics is loud and clear: there’s going to be no more investment in the antibiotic yeast infection symptoms female sector until there is substantial change in the marketplace.”

In many ways, the escalation of antimicrobial resistance is the product of a yeast infection symptoms female collision between two omnipresent threats facing the pharmaceutical industry: the scientific challenge of developing new treatments and market failures yeast infection symptoms female that thwart their pathway to commercial success.

Zimmerman is at the helm of one of the biotech yeast infection symptoms female companies developing “truly novel” antibiotics, rather than new iterations of existing classes. But forge — along with companies such as entasis therapeutics inc. Of waltham, mass., melinta therapeutics inc. Of new haven, conn., and tetraphase pharmaceuticals inc. Of watertown, mass. — is not exploring uncharted territory. And top executives are acutely aware of how this story yeast infection symptoms female ends in the absence of a market fix.

Achaogen inc., a drugmaker based in south san francisco, calif., that spent years developing an antibiotic for a drug-resistant infection commonly found in intensive care settings, filed for chapter 11 bankruptcy in april, less than a year after its treatment zemdri won federal yeast infection symptoms female approval. Several other companies with late-stage antibiotics have already undergone rounds of layoffs, gutted research programs or begun selling laboratory equipment.

Greg frank, the director of infectious disease policy at the biotechnology innovation yeast infection symptoms female organization, said achaogen’s fate sent a grave signal to companies in this yeast infection symptoms female space that are clamoring to prove their products’ success before cash runs out.

“achaogen was the first to go bankrupt. If three or four more companies also go bankrupt, the ripple effects this will have on what’s left of the antimicrobial pipeline will be quite dire,” frank said. “we need to have swift action and signs from the yeast infection symptoms female U.S. Government, congress and the administration that they are really acting on yeast infection symptoms female this issue and trying to address it comprehensively.”

Frank is spearheading “ working to fight AMR ,” the first public-facing coalition sounding the alarm on this issue in washington. The group’s first order of business is advocating for legislation to yeast infection symptoms female catalyze development of new medication, most notably sens. Johnny isakson (R-ga.) and bob casey’s (D-pa.) DISARM act , which would adjust how medicare reimburses hospitals for certain antibiotics yeast infection symptoms female and offer additional funding to hospitals when qualifying drugs are yeast infection symptoms female appropriately deployed.

Eric kimble, chief commercial officer at entasis, said that by nature, antibiotics — short-term drugs intended to be a lifesaving last resort — face a unique set of “perverse” incentives riddling the health system that threatens investment in this yeast infection symptoms female arena. For one, hospitals are reimbursed at lower rates for using novel, pricier medications, even if lower-cost generics are drug-resistant. The disincentive for buying new products means antibiotics don’t drive profit, and financial backers don’t see a solid return on their investment.

The DISARM act is no silver bullet, but industry leaders say the investor community has indicated its yeast infection symptoms female passage would send a message in favor of giving these yeast infection symptoms female antibiotic-focused companies a lifeline. Until then, biotech companies are trying to make their limited financial resources yeast infection symptoms female last.

Boston-based paratek pharmaceuticals inc. Has a drug for urinary tract infections in phase two yeast infection symptoms female of a clinical trial now, but adam woodrow, the company’s president and chief commercial officer, says it will be very difficult to raise the financial yeast infection symptoms female capital for phase three — despite the fact that paratek is in a relatively healthy yeast infection symptoms female position compared to others in its peer group and is yeast infection symptoms female currently selling that drug to treat community acquired bacterial pneumonia yeast infection symptoms female and acute skin infections. Ruben tommasi, chief scientific officer at entasis, said the drugmaker has just enough on hand to “crack the envelope” for one of its products to determine whether it’s been successful, but no more after that.

From a public health perspective, there are frightening parallels between the rise of superbugs and yeast infection symptoms female the opioid epidemic, zimmerman noted. The government was warned by federal scientists of the mounting yeast infection symptoms female risk of opioid addiction and abuse; in the same vein, infectious disease experts have been monitoring drug-resistant bacteria across the globe and the united states for yeast infection symptoms female decades and “know it’s only going to get worse.”

What’s more, drug resistance is already here. The centers for disease control and prevention has changed its yeast infection symptoms female guidelines for gonorrhea treatment six times in the past 20 yeast infection symptoms female years because of the infection’s aptitude for developing resistance. The risk of bankruptcy for companies desperately seeking funding to yeast infection symptoms female develop antibiotics is a matter of a couple years, if that.

According to zimmerman, forge has heard some positive news from federal agencies about yeast infection symptoms female a market stabilization initiative — perhaps a fixed-purchase or stockpile process that would guarantee companies some flow yeast infection symptoms female of revenue. That’s critical, he said, because companies need ammunition to show investors that even if yeast infection symptoms female a product isn’t a blockbuster, it can deliver solid returns on investment.

Experts acknowledged that recent action by the centers for medicare yeast infection symptoms female and medicaid services on addressing reimbursement challenges has been promising, but they aren’t stopping to celebrate any victories just yet. In the meantime, some companies are eyeing opportunities for consolidation.

RELATED POSTS